FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year. https://t.co/b5hOwTxWaU https://t.co/Wq5EsZGLK5
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition
FibroGen sells China unit to AstraZeneca for $160 million
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
218.02BUSD
タイプ
Common Stock
取引所
PINK
通貨コード
USD
通貨名
US Dollar
国名
USA
国のISOコード
US
ISIN
GB0009895292
CUSIP
-
セクター
Healthcare
業種
Drug Manufacturers - General
会計年度末
December
上場日
-
更新日時
-
PER
28.31
PEGレシオ
0.92
簿価
26.48
1株当たり配当金
3.1
配当利回り
2.31%
希薄化後1株当たり利益
4.97
ウォールストリートの目標株価
-
EPS見通し(現在の年度)
-
EPS見通し(次の年度)
-
EPS見通し(現在の四半期)
0
EPS見通し(次の四半期)
0
直近の四半期
-
売上高TTM
54,982,000,640
粗利益TTM
45,328,998,400
EBITDA
18,276,999,168
利益率
14.14%
総資産利益率TTM
8.16%
自己資本利益率TTM
19.79%
一株当たり売上高TTM
35.467
四半期売上高成長率(前年同期比)
7.20%
希薄化後EPS TTM
4.97
四半期利益成長率(前年同期比)
33.60%
トレーリングPER
28.31
フォワードPER
15
株価/売上高TTM
3.9877
株価/帳簿価格MRQ
5.2196
企業価値/売上高
4
企業価値/EBITDA
15
189.96
2.31%71.49
2.29%155.83
2.09%69.48
1.80%123.10
1.69%324.58
0.31%120.00
0.00%333.36
-1.95%776.35
-0.41%40.79
-0.29%